ERC Announces Interim Results from Phase 2 Trial of Immunotherapy ERC1671 in Recurrent Glioblastoma Patients

On August 18, 2020 ERC Belgium, a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer, reported promising interim results in the phase 2 clinical trial for ERC1671 (also known as Gliovac or SITOIGANAP) under FDA IND 15430 at the University of California, Irvine Medical Center in Orange, California (Press release, ERC Belgium, AUG 18, 2020, View Source [SID1234563790]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial, "ERC1671/GM CSF/Cyclophosphamide+Bevacizumab vs Placebo," is a double-blind, placebo-controlled study of 84 patients with recurrent GBM. Interim unblinding and analysis of the first 10 patients from the study demonstrated the following results in patients treated with ERC1671:

6-month overall survival (OS) rate of 100%;
12-month OS rate of 40%;
Median OS is 46 weeks (10.5 months)
Historic controls have 6-month OS rate of 33% and median OS of 23 weeks (5.3 months). This dataset reveals a striking improvement over current clinical practice and the results demonstrate a highly significant (log rank test, p < 0.0001) increase in the OS of patients when treated with ERC1671.

Approximately 10% of the patients receiving ERC1671 experienced total recovery and survived longer than 3 years when treated following GBM recurrence and after receiving standard of care treatment. In contrast, no spontaneous remissions were observed in the control group and all patients experienced tumor progression.

Furthermore, a subgroup of patients who had failed treatment with bevacizumab (Avastin) benefited disproportionately with an apparent doubling of survival compared to historical controls.

Principal investigator of the clinical trial, Daniela Bota, MD, PhD, commented, "Prior to this study of ERC1671 immunotherapy for recurrent GBM, it was almost unknown for such patients to experience recovery. We are excited to accelerate recruitment and complete this study." Dr. Bota is Vice Dean for Clinical Research, Medical Director, UCI Center for Clinical Research; Director, UCI Alpha Stem Cell Clinic; Medical Director, UCI Health Comprehensive Brain Tumor Program.

Apostolos Stathopoulos, MD, PhD, President and CEO of ERC Worldwide commented, "We are encouraged by such strong results for ERC1671 in Dr. Bota’s study and pleased to see a high number of patients going into remission. We believe that ERC1671 is finally leading the way for immunotherapy to treat intractable cancers like recurrent GBM that currently do not have alternative therapeutic options."

About ERC1671

ERC1671 (Gliovac or SITOIGANAP) is an advanced immunotherapy based on freshly extracted tumor cells and lysates that stimulates the patient’s immune system to recognize and reject cancer cells. The immunotherapy contains a combination of autologous tumor cells, and allogeneic tumor cells, generated from the glioma tumor tissues of three different donor cancer patients, and the lysates of all of these cells. Upon injection, this mixture stimulates the patient’s immune system to mount an immune response against the tumor cells, which may lead to their destruction.

ERC1671 is for patients suffering from a grade IV glioma (glioblastoma multiforme and gliosarcoma) when all other traditional treatments have failed. The response to SITOIGANAP is the same whether the MGMT promoter is methylated or unmethylated.

ERC1671 is currently in randomized, placebo-controlled Phase 2 clinical trials in the United States as part of combination treatment for glioblastoma multiforme and gliosarcoma.

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

On August 18, 2020 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, reported it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020 (Press release, Aeglea BioTherapeutics, AUG 18, 2020, View Source [SID1234563775]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Panel Title: Stronger Together: Continuing industry and patient partnerships to ensure inclusion of patient voice along the full continuum of development, from pre-clinical through commercialization
Date/Time: August 24 at 9:10 a.m. EDT
Moderator: Michael C. Hanley, Aeglea’s chief commercial officer

Presentation Title: Next generation human enzymes: Innovative solutions for patients with rare diseases
Date/Time: August 25 at 12:50 p.m. EDT
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer

The company presentation will be available for download on the Presentations & Events section of the Company’s website.

Genosity Receives CLIA Approval for AsTra Profile™ and AsTra Next™ to Enable Earlier Detection of Cancer Relapse Through Patient-Specific Liquid Biopsy Monitoring

On August 18, 2020 Genosity Inc., reported that it has received CLIA approval for its tumor exome and liquid biopsy cancer monitoring platform, AsTra (Assessment and Tracking), designed to identify a patient’s unique tumor molecular profile that can be used for ongoing, personalized Minimal Residual Disease (MRD) monitoring (Press release, Genosity, AUG 18, 2020, View Source [SID1234563792]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Astra testing system enables the assessment and tracking of a patient’s individual and unique tumor genetic signature by employing a multi-step testing strategy. Astra Profile, the first component of the system relies on a comprehensive tumor profile collected through whole exome sequencing on the Illumina NovaSeq 6000 platform to identify each tumor’s unique molecular fingerprint. This fingerprint is then leveraged to generate a patient specific molecular assay using a third-party library prep technology. Astra One, the second component of the system enables detection of the tumors unique signature and initial MRD assessment through non-invasive liquid biopsy. Astra Next, the third component of this platform allows ongoing monitoring and MRD assessment through liquid biopsy as well. The comprehensive platform provides an ability to detect the presence of relapse or residual disease and potentially enable earlier management interventions.

"Next Generation sequencing continues to expand the frontiers of precision medicine. With advances in the Illumina Sequencing technology, we are able to cost effectively leverage a comprehensive Tumor Exome combined with subsequent liquid biopsies to enable truly personalized recurrent and residual disease monitoring" says Dr. Robert Daber, President and CTO of Genosity, Inc. "Working with biopharma and other partners, we are committed to supporting the development of innovative technologies that have the potential to accelerate precision medicine and improve clinical outcomes. The ability to initiate earlier interventions through routine non-invasive testing is disruptive."

Genosity continues to expand its Oncology offerings for research and clinical research applications specifically focused on meeting the needs of the biopharmaceutical community. Genosity is currently working on a variety of innovative pharma projects spanning translational research to late stage clinical trials. Genosity has become an ideal partner for biotech and biopharma companies seeking to advance disruptive genomics technologies due to its synergistic strategic approach of combining the capabilities of a sophisticated central laboratory with its proprietary commercial genomics software solution including a genomics laboratory information management system (LIMS) and reporting platform to assist with distribution and implementation of these research and clinical research assays.

Emergent BioSolutions to Participate in Virtual Investor Conferences

On August 18, 2020 Emergent BioSolutions Inc. (NYSE: EBS) reported that members of the company’s executive management team will participate in the following virtual investor conferences through the end of September 2020 (Press release, Emergent BioSolutions, AUG 18, 2020, View Source [SID1234569794]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2020 NYSE Healthcare & Technology Investor Access Day
August 18 – virtual one-on-one meetings only

2020 Three Part Advisors Virtual Midwest IDEAS Investor Conference
August 27 – pre-recorded presentation available beginning at 8:00am eastern

2020 Wells Fargo Virtual Healthcare Conference
September 9 – presentation at 8:00am eastern

Robert W. Baird 2020 Global Healthcare Conference
September 10 – presentation at 2:35pm eastern

Morgan Stanley 18th Annual Global Healthcare Conference 2020
September 14 – presentation at 4:30pm eastern

Cantor Virtual Global Healthcare Conference 2020
September 15 – presentation at 3:20pm eastern

2020 Singular Research Compelling Values Webcall
September 17 – presentation at 12:00pm eastern
For conferences where a presentation is planned, the company’s webcast presentation may include a discussion of the company’s recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the Emergent website www.emergentbiosolutions.com under "Investors."

BerGenBio ASA: Results for the Second Quarter and First Half of 2020

On August 18, 2020 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need indications, reported its results for the second quarter and first half of 2020 (Press release, BerGenBio, AUG 18, 2020 View Source [SID1234563725]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below for details.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "Set against the unprecedented backdrop of a global pandemic, this has been an eventful period for BerGenBio. During this time we have continued our focus on progressing clinical trials of our lead candidate bemcentinib in non-small cell lung cancer (NSCLC) and Acute Myeloid Leukaemia (AML) and more recently COVID-19, while ensuring that the safety and wellbeing of our staff and the patients participating in our clinical trials has been and remains our top priority.

"The COVID-19 crisis has and will likely continue to delay clinical trials throughout the sector and as anticipated has impacted patient recruitment into BerGenBio clinical studies and extended previously anticipated timelines. The impact of the pandemic on our clinical trials has continued through the second quarter, but we are pleased that new patients continue to be recruited into our clinical studies with bemcentinib, and already enrolled patients have been able to continue their treatment throughout the restrictions.

"We continue to make progress, with a latest milestone in NSCLC trial presented at the Next Gen Immuno-Oncology Congress conference where 6 of the 7 identified AXL positive patients reported clinical benefit and data showed a 2.5-fold improvement in median Progression-free Survival.

"The Company remains in a strong cash position, with two drug candidates backed by pioneering biology, continued favourable clinical results and important data readouts on the horizon in two major cancer indications, as well as a potential COVID-19 treatment. This is an exciting time for us."

Operational Highlights – second quarter and the first half of 2020 (including post-period end)

Positive interim clinical and translational phase II data with bemcentinib in combination with KEYTRUDA in checkpoint inhibitor refractory NSCLC patients
In June, BerGenBio presented positive data from its Cohort B, stage 1, in the phase II trial evaluating bemcentinib in combination with KEYTRUDA in patients with advanced non-small cell lung cancer (NSCLC) and with confirmed progression on prior immune checkpoint therapy.
The trial included 12 evaluable patients for cAXL, BerGenBio’s proprietary composite-AXL (cAXL) immunohistochemistry biomarker. 7 of these 12 patients were cAXL-positive whereby 6 of these 7 patients reported clinical benefit and 2.5-fold improvement in mPFS.
BerGenBio also reported an update on Overall Survival data from Cohort A, where cAXL-positive patients reported 12-month Overall Survival of 79% and median Overall Survival of 17.3 months, whereas cAXL-negative reported 60% and 12.4 months respectively.
Data was presented at the NextGen Immuno-Oncology Congress, 25 June
First patient dosed in bemcentinib COVID-19 study in June 2020
In April, BerGenBio announced the selection of bemcentinib as the first candidate in a UK Government-backed national ACCORD study.
The study was a multicentre, seamless, Phase II adaptive randomisation platform trial to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised UK NHS patients, and the first patient was dosed in June.
At the end of July, the incidence of COVID-19 in the UK had drastically reduced and the UK Research and Innovation’s (UKRI) decided to cease grant funding. Subsequently, the University Hospital Southampton NHS Trust notified all sites in the ACCORD programme to cease the recruitment of new patients into the trial for all candidate agents. Patients already recruited, including those dosed with bemcentinib, will continue on treatment as per the protocol.
The decision to halt the study reflected the significant decrease in the incidence of COVID-19 in the UK and difficulty recruiting a sufficient number of patients and in no way reflected any interpretation of the efficacy or safety of any of the candidate agents.
BerGenBio is now in the late stage set-up phase to sponsor a similar study to ACCORD in a country of high COVID-19 incidence.
First patient dosed in bemcentinib Glioblastoma study in July 2020 (post-period)
In July, BerGenBio announced the first patient was dosed in an investigator-initiated trial (IIT) assessing bemcentinib in recurrent glioblastoma (GBM). The study will enrol up to 20 recurrent GBM patients, at up to 15 sites in the USA.
Increased expression of the receptor tyrosine kinase AXL is significantly correlated with poor prognosis in GBM patients and preclinical data has suggested that bemcentinib may be a promising therapeutic agent for GBM, particularly in post-irradiation mesenchymal-transformed GBM tumors.
A comprehensive translational research programme will run in parallel with the clinical trial.
Q2 2020 Financial Highlights

(Figures in brackets = same period 2019 unless otherwise stated)

Revenue for the second quarter amounted to NOK 0.0 million (NOK 0.0 million) and for the six months ended 30 June NOK 0.0 million (NOK 8.7 million). The revenue in 2019 reflects clinical milestone payments from ADCT.
Total operating expenses for the second quarter amounted to NOK 64.7 million (NOK 52.0 million) and for the six months ended 30 June NOK 121.0 million (NOK 106.5 million). NOK 7.5 million (NOK – 2.5 million) of operating expenses was non cash accruals for option cost.
The operating loss for the quarter came to NOK 64.7 million (NOK 52.0 million) and for the six months ended 30 June NOK 121.0 million (NOK 97.8 million), reflecting the level of activity related to the clinical trials BerGenBio are conducting.
Cash and cash equivalents increased to NOK 828.4 million by 30 June (NOK 419.4 by 31 March 2020).
Private placement completed in May 2020, with gross proceeds NOK 520 million (including NOK 20 million from repair issue in July). Net proceeds to be used to take full advantage of clinical development opportunities stemming from the Company’s technology and to progress readiness for early commercialisation possibilities and general corporate purposes.
Presentation and Webcast Details

A presentation by BerGenBio’s senior management team will take place today at 10:00 am CET:

The second quarter report and presentation is available on the Company’s website in the Investors/Financial Reports section and a recording of the webcast will be made available shortly after the webcast has finished.